Overview

A Study of JNJ-64407564 in Japanese Participants With Relapsed or Refractory Multiple Myeloma

Status:
Recruiting
Trial end date:
2023-01-09
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability in Japanese participants with relapsed or refractory multiple myeloma (MM) at the recommended Phase 2 dose (RP2D) identified in NCT03399799 study.
Phase:
Phase 1
Details
Lead Sponsor:
Janssen Pharmaceutical K.K.